Related Experiment Videos
Quantitative assay for the radiosensitivity of malignant melanomas
E C Krishnan1, L Krishnan, G D Schweiger
1Department of Surgery, University of Kansas Medical Center, Kansas City 66160-7321.
Melanoma Research
|June 1, 1994
Summary
Malignant melanomas may be less resistant to radiation than previously thought. A study using a B16 mouse model found that a single 18 Gy radiation dose made 99% of surviving melanoma cells non-clonogenic, suggesting potential for effective radiation therapy.
Area of Science:
- Oncology
- Radiation Biology
- Cancer Research
Background:
- Malignant melanomas exhibit controversial radiosensitivity, with some studies suggesting radioresistance due to a large shoulder on cell survival curves.
- Lack of consensus exists regarding optimal radiation fractionation for melanoma treatment, considering total dose, fraction size, and interfraction intervals.
Purpose of the Study:
- To evaluate the radiosensitivity of B16 mouse melanoma cells in vivo.
- To quantify the effect of single radiation doses on melanoma cell clonogenicity and tumor growth kinetics.
- To establish a bioassay for assessing melanoma radiosensitivity and informing treatment strategies.
Main Methods:
- Utilized a B16 mouse melanoma model for in vivo irradiation experiments.
- Administered single doses of radiation to tumors and assessed subsequent tumor growth kinetics.
- Quantified radiosensitivity by comparing tumor growth from irradiated versus unirradiated melanoma cell inocula of varying cell numbers.
Main Results:
- A single dose of 18 Gy radiation rendered approximately 99% of surviving B16 melanoma cells non-clonogenic.
- The study established a bioassay to evaluate the growth kinetics of irradiated and unirradiated tumor cells.
Conclusions:
- The findings challenge the notion of melanoma radioresistance, indicating significant radiosensitivity under specific irradiation conditions.
- The developed bioassay provides a foundation for optimizing radiation fractionation schemes for malignant melanoma treatment.